EP Patent

EP0061333A1 — 9-(2-(3-Indolyl)ethyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones

Assigned to Syntex USA LLC · Expires 1982-09-29 · 44y expired

What this patent protects

Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula wherein: R, R 1 , R 2 , R 3 , and R 4 are independently hydrogen or lower alkyl of one …

USPTO Abstract

Compounds useful in the prevention and/or treatment of hypertension, congestive heart failure, arrhythmia, migraine, vasospastic disorders, and asthma are represented by the formula wherein: R, R 1 , R 2 , R 3 , and R 4 are independently hydrogen or lower alkyl of one to four carbon atoms; and R 5 and R 6 are independently hydrogen, lower alkyl of one to four carbon atoms or lower alkoxy of one to four carbon atoms; and the pharmaceutically acceptable acid addition salts thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP0061333A1
Jurisdiction
EP
Classification
—
Expires
1982-09-29
Drug substance claim
No
Drug product claim
No
Assignee
Syntex USA LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.